GLP-1 Drugs Linked to Reduced Long-Term Sick Leave, Danish Study Suggests

Miami Fort Lauderdale, FL, July 24, 2026 —

A study examining data from Denmark indicates a potential link between the use of GLP-1 drugs and a significant decrease in long-term sick leave among recipients.

The research, which analyzed health records from Denmark, found that individuals prescribed GLP-1 receptor agonists experienced an average reduction of 17% in long-term sick leave.

GLP-1 drugs are primarily known for their role in managing type 2 diabetes and obesity, aiding in blood sugar control and appetite regulation. This new data suggests a broader potential impact on workforce participation and employee well-being.

The study’s findings are based on an analysis of Danish data, and the specific methodologies and the exact timeframe of the study were not detailed in the provided summary. Further details regarding the patient cohorts, duration of GLP-1 drug use, and the definition of “long-term sick leave” within the study’s parameters would be necessary for a comprehensive understanding of the results.

The contractor or researchers responsible for conducting this study were not named. Additionally, the specific GLP-1 medications included in the analysis and the exact source of the Danish data remain unspecified.

While the study points to a 17% reduction, the full scope of factors contributing to this observed decrease in sick leave is not elaborated upon. Potential confounding variables that might influence sick leave rates, such as socioeconomic status, other concurrent health conditions, or workplace policies, were not detailed.

Story summarized from the original created by Steph Whiteside on thehill.com, see more information here.

Media gallery